Form 4: Director Carl Howard Receives Equity Awards

AC Immune SA Director Carl Howard was granted restricted stock units and stock options on June 11, 2026, as disclosed in a Form 4 filing.

Summary

• Director Carl Howard of AC Immune SA received a grant of 16,568 restricted stock units (RSUs) on June 11, 2026, under the company's 2016 Stock Option and Incentive Plan (SOIP).
• Additionally, on the same date, Howard was granted options to purchase 38,889 common shares under the SOIP.
• These options are set to fully vest on June 10, 2027.
• Following these transactions, Howard beneficially owns 67,556 common shares, which includes the 66,556 common shares underlying outstanding RSUs.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports routine equity grants to a director, which is standard practice and does not inherently signal significant positive or negative developments for the company's financial performance or strategic direction.

Positives

• Director Carl Howard received equity awards, indicating continued alignment with shareholder interests.
• The grant of RSUs and stock options suggests a long-term incentive structure for key personnel.
• The reporting person has a significant beneficial ownership of 67,556 common shares.

Future Outlook

The stock options granted to Carl Howard will fully vest on June 10, 2027, and expire on June 10, 2036, indicating a long-term commitment and incentive structure.

Industry Context

StockSavvy.ai notes that the issuance of equity awards like restricted stock units and stock options to directors is a common practice in the biotechnology and pharmaceutical sectors to attract, retain, and incentivize key leadership, aligning their interests with those of shareholders.

Stakeholder Impact

• Shareholders: The equity grants to Director Carl Howard align his interests with those of shareholders through long-term equity incentives.
• Employees: The SOIP mentioned in the filing suggests a broader framework for employee equity compensation, potentially impacting morale and retention.
• Management: The grants reinforce the compensation structure for senior leadership.

Next Steps

• The stock options granted will vest on June 10, 2027.
• The stock options will expire on June 10, 2036.

Key Dates

Keywords

AC Immune SA, ACIU, Form 4, Director, Equity Awards, Restricted Stock Units, Stock Options, Beneficial Ownership, Securities Exchange Act